Rituxan (rituximab) - Roche
IgG4-to-IgG Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in IgG4-Related Disease. (PubMed, ACR Open Rheumatol) - Sep 25, 2026 - "In a diverse IgG4-RD cohort, disease phenotypes were consistent across races, though treatment access disparities existed. Dynamic changes in IgG4-to-IgG ratios and the presence of orbital disease are key predictors of response to rituximab, informing personalized treatment strategies." 
Journal • Inflammation • Rheumatology
http://www.ncbi.nlm.nih.gov/pubmed/42782189
 
Alejandro Quinteros; Galina Marder; Lara El Khoury; Morris Clive Edelman; Pallavi Khattar; Young Min Cho
 
Sep 25, 2026
 
Prev Next